Effect of Oral Gabapentin and Pregabalin in the Management of Neuropathic Pain in Palliative Care Patients: An Institution-based Comparative Study

Nipun Lamba1, Ruchika Makkar2, Namita Gupta3, Sudha Sarna4, Seema Khandelwal5

ABSTRACT
Background: Gabapentin and pregabalin are antiepileptic drugs used in the treatment of neuropathic pain. They are used as adjuvants with analgesics in the management of pain.
Aims and objectives: We aimed to compare gabapentin and pregabalin’s role in neuropathic pain in cancer patients.
Materials and methods: This prospective, comparative study included 100 patients having neuropathic pain, undergoing cancer treatment in Mahatma Gandhi Hospital.
Results: The mean age of patients was 38.2 ± 8.2 in the gabapentin group and 37.4 ± 7.4 in the pregabalin group. Headache was the most common among the gabapentin group, followed equally by placebo and pregabalin groups. Nausea was equally reported by the gabapentin and placebo groups. Dizziness was seen equally among the placebo and pregabalin groups followed by the gabapentin group.
Conclusion: The study concluded that pregabalin is a better medication for the management of neuropathic pain as compared to gabapentin.
Keywords: Cancer, Gabapentin, Palliative care, Pregabalin.

INTRODUCTION
Neuropathic medications are increasingly being used in the management of neuropathic pain along with adjuvants in the management of pain. Pain in cancer is the most fearsome symptom along with the disease itself. Proper management of pain is necessary. Multimodal analgesia and newer medications had reduced the incidence of neuropathic as well as postsurgical pain.1 It was observed that when we are unable to give proper analgesic pain worsens and the patient might need admission again causing an increase in financial burden.2 Because of neuropathic pain quality of life is hampered.3,4 Sleep disturbances, anxiety, and various other problems may coexist.4 It was observed that giving pain medicines before painful stimulus gives better results than giving after.5

MATERIALS AND METHODS
We had undergone a present study in the Department of Pain and Palliative Medicine, Mahatma Gandhi Medical College and Hospital, Jaipur, India. The study design was a prospective randomized observational study of 100 patients suffering from cancer having painful neuropathy. In a prospective randomized study, 50 patients were allocated randomly into two equal groups.

Due permission was taken from the institutional ethics committee and after obtaining written informed consent from patients. Patients in group G were given gabapentin 300 mg at bedtime whereas group P received pregabalin 75 mg. The pain was recorded using the VAS scale. Follow-up was done over a period of a month (Tables 1 to 4).
We have formed two groups for comparison.
- Group I: 50 cases, were given pregabalin, beginning with 75 mg.
- Group II: 50 cases, were given gabapentin, beginning with 300 mg.

Table 1: Patients demographics

|                | Pregabalin (n = 50) | Gabapentin (n = 50) | p value |
|----------------|---------------------|---------------------|---------|
| Age (years)    | 37.4 ± 7.4          | 38.2 ± 8.2          | >0.05   |
| Sex male/female| 22/28               | 18/32               | >0.05   |
| Weight (kg)    | 72.4 ± 5            | 71 ± 6              | >0.05   |

The mean age in the pregabalin group was 37 ± 7.4 and gabapentin was 38.2 ± 8.2, having a p value > 0.05. These groups were comparable. Weight in the pregabalin group was 72.4 ± 5 and gabapentin was 71 ± 6, p value > 0.05.

Inclusion Criteria
- Patients undergoing cancer treatment having neuropathic pain.

© Jaypee Brothers Medical Publishers. 2021 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Effect of Oral Gabapentin and Pregabalin in the Management of Neuropathic Pain in Palliative Care Patients

Table 2: Incidence of burning sensation

| Duration in weeks | Study population with a burning sensation |
|-------------------|-------------------------------------------|
|                   | Pregabalin (n = 50)                      | Gabapentin (n = 50) |
|                   | No. of cases | %     | No. of cases | %     |
| Baseline          | 50           | 100.0 | 50           | 100.0 |
| 1 Week            | 46           | 92.0  | 47           | 94.0  |
| 2 Weeks           | 45           | 90.0  | 48           | 96.0  |
| 3 Weeks           | 44           | 88.0  | 47           | 94    |
| 4 Weeks           | 40           | 80.0  | 42           | 84.0  |

A burning sensation is reduced at 1, 2, 3, and 4 weeks 92, 90, 88, and 80% and in gabapentin in 94, 96, 94, and 84%

Table 3: Incidence of spontaneous pain

| Duration in weeks | Study population with spontaneous pain |
|-------------------|----------------------------------------|
|                   | Pregabalin (n = 50)                     | Gabapentin (n = 50) |
|                   | No. of cases | %     | No. of cases | %     |
| Baseline          | 40           | 80.0  | 39           | 78.0  |
| 1 Week            | 38           | 76.0  | 37           | 74.0  |
| 2 Weeks           | 36           | 72.0  | 36           | 72.0  |
| 3 Weeks           | 34           | 68.0  | 36           | 72.0  |
| 4 Weeks           | 33           | 66.0  | 34           | 68.0  |

Spontaneous pain at 1, 2, 3, and 4 weeks showed more improvement with pregabalin than gabapentin

Table 4: VAS score

| VAS score       | Pregabalin | Gabapentin |
|-----------------|------------|------------|
| Baseline        | 8.64 ± 2.80| 8.62 ± 3.57|
| At 4 weeks      | 3.96 ± 5.54| 4.62 ± 4.89|
| Mean improvement| 4.68 ± 4.97| 4.00 ± 4.54|

VAS score improvement in the pregabalin group was 8.64 ± 2.80 and in the gabapentin group, 8.62 ± 3.57 at 4 weeks was 3.96 ± 5.54 and in gabapentin 4.62 ± 4.87. Mean improvement 4.68 ± 4.97 and the gabapentin group was 4.00 ± 4.54

Discussion

Cancer-related pain is the most common cause of morbidity and mortality. Neuropathic pain causes distress and financial losses. We have compared gabapentin and pregabalin for the management of neuropathic pain in cancer patients. Respective medications were given for 30 days and their effects on pain, burning sensation were seen. Also, their adverse effects were noted, and numbness was evaluated. The pain was evaluated by the use of the VAS scale and the patients’ response. Yilmaz et al. found no statistically significant difference between gabapentin and pregabalin in neuropathic pain. Richter et al. reported that pregabalin 300 mg/day provides >50% reduction in pain from baseline in about 40% of total patients. Rosenstock et al. described a 67% reduction in neuropathic pain in patients treated with pregabalin.

Lesser et al. also reported that gabapentin and pregabalin groups provide better pain relief than which was also in accordance with the findings of the current study.

Gabapentin and pregabalin are used for the management of neuropathic pain in cancer patients, both are effective in the management of pain

Conclusion

According to the results of our study, both gabapentin and pregabalin are suitable adjuvants along with analgesics for the management of neuropathic pain in cancer patients.

References

1. Vadivelu N, Mitra S, Narayan D. Recent advances in postoperative pain management. Yale J Biol Med 2010;83(1):11–25.
2. Sinatra R. Causes and consequences of inadequate management of acute pain. Pain Med 2010;11(12):1859–1871. DOI: 10.1111/j.1526-7555.2009.00983.x.
3. Rodriguez MJ, Diaz S, Vera-Llonch M, et al. Cost-effectiveness analysis of pregabalin versus gabapentin for the management of neuropathic pain due to diabetic polyneuropathy or postherpetic neuralgia. Curr Med Res Opin 2007;23(10):2585–2596. DOI: 10.1185/030079907X233151.
4. Navarro A, Saldaña MT, Pérez C, et al. A cost-consequences analysis of the effect of pregabalin in the treatment of peripheral neuropathic pain in routine medical practice in primary care settings. BMC Neurol 2011;11(1):1. DOI: 10.1186/1471-2377-11-7.
5. Saraswat V, Arora V. Preemptive gabapentin vs pregabalin for acute postoperative pain after surgery under spinal anaesthesia. Ind J Anaes 2008;52:829–834.
6. Yilmaz B, Yasar E, Koroglu OQ, et al. Gabapentin vs pregabalin for the treatment of neuropathic pain in patients with spinal cord injury: a crossover study. Turk J Phys Med Rehab 2014;60(1):1–5. DOI: 10.1185/030079907X233151.
7. Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005;6(4):253–260. DOI: 10.1016/j.jpain.2004.12.007.
8. Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo controlled trial. Pain 2004;110(3):628–638. DOI: 10.1016/j.jpain.2004.05.001.
9. Lesser H, Sharma J, LaMoreaux L, et al. Pregabalin relieves symptoms of painful diabetic neuropathy. A randomized controlled trial. Neurology 2004;63(11):2104–2110. DOI: 10.1212/01.wnl.0000145767.36287.a1.
10. Mishra R, Tripathi M, Chandola HC. Comparative clinical study of gabapentin and pregabalin for postoperative analgesia in laparoscopic cholecystectomy. Anesth Essays Res 2016;10(2):201–206. DOI: 10.4103/0259-1162.176409.

There was an incidence of nausea, vomiting, dizziness, drowsiness, headache, and visual disturbances. There was no incidence of urinary retention and respiratory depression.